Loading
A phase 3 trial of Trastuzumab brengitecan, Pembrolizumab, Pemetrexed in non-small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC is a phase 3 interventional study registered as NCT07178795 by Sichuan Baili Pharmaceutical Co., Ltd., with 440 participants planned, started 2025-09-29 and due to reach its primary completion in 2027-12. Interventions recorded: BL-M07D1, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin. Conditions listed: Non-squamous Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trastuzumab brengitecan, HER2-mutant non-small-cell lung cancer, SystImmune / Sichuan Biokin, Pembrolizumab.
Shares Trastuzumab brengitecan, HER2-mutant non-small-cell lung cancer, SystImmune / Sichuan Biokin, Non-small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
Shares HER2-mutant non-small-cell lung cancer, Pemetrexed, Cisplatin, Carboplatin.
Shares HER2-mutant non-small-cell lung cancer, Pemetrexed, Cisplatin, Carboplatin.
Shares HER2-mutant non-small-cell lung cancer, Pemetrexed, Cisplatin, Carboplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/